Administration of Donor MultiTAA-Specific T Cells for ALL

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

October 29, 2019

Study Completion Date

November 18, 2024

Conditions
Leukemia, Lymphoblastic (Acute)
Interventions
BIOLOGICAL

MultiTAA-specific T cells

"The 3 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients being treated on Arm A (adjuvant) or Arm B (active disease) who have a partial response, complete response or stable disease, will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions at a minimum of 4 weeks apart."

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

lead

Baylor College of Medicine

OTHER

NCT02475707 - Administration of Donor MultiTAA-Specific T Cells for ALL | Biotech Hunter | Biotech Hunter